ZOM - Zomedica Pharmaceuticals Corp.

NYSE American - NYSE American Delayed Price. Currency in USD
2.25
+0.06 (+2.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.19
Open2.19
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.13 - 2.33
52 Week Range1.75 - 2.98
Volume32,853
Avg. Volume98,958
Market Cap236.09M
Beta-1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire23 days ago

    Zomedica Announces Interim Closing and Extension of Its Private Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (the “Company”), a veterinary diagnostic and pharmaceutical company, announced today that it has effected an interim closing of its previously announced private offering of common shares, resulting in the sale of 1,605,812 common shares for gross proceeds of $3,452,496 (C$4,415,983). As previously announced, the Company is offering an aggregate of up to 4,651,162 common shares at a price of $2.15 (C$2.75) per share for aggregate gross proceeds of up to $10,000,000 (C$12,790,700) in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder.

  • GlobeNewswire26 days ago

    Zomedica Joins Russell 3000™ and Russell Microcap® Indexes

    ANN ARBOR, Mich., June 25, 2018-- Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, today announced that the Company joined the Russell 3000™ Index and the Russell Microcap ...

  • GlobeNewswirelast month

    Zomedica Provides Product Development Update

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today provided a product development update. As previously disclosed, Zomedica has partnered with Celsee, Inc. (“Celsee”) to develop Celsee’s circulating tumor cell, or CTC, assay, also known as a “liquid biopsy” for use by veterinarians as a cancer diagnostic. The liquid biopsy is a blood test that we believe has the potential to detect the presence of CTCs, which are cells that have shed from a primary tumor into neighboring blood vessels and are transported throughout the body’s circulatory system.

  • GlobeNewswirelast month

    Zomedica Announces Changes to Commercialization Leadership Team

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Michael Schilk as Vice President of Sales and David Eaton as Vice President of Marketing. Michael Schilk joins Zomedica with more than 25 years of global sales and business development experience in both the human and animal health markets, including time at multiple Fortune 500 companies. Throughout his career, Schilk has been responsible for leading the commercial launch of pharmaceutical and diagnostic products across North America, Europe, Asia and Latin America and has held senior roles at Abbott Laboratories and Pfizer Inc., among others.

  • GlobeNewswire2 months ago

    Zomedica Pharmaceuticals Corp. Announces First Quarter 2018 Financial Results

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the first quarter ended March 31, 2018. On May 10, 2018 Zomedica announced it entered into a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. to develop and market a novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument. On May 15, 2018 Zomedica announced it commenced a private offering of its common shares offering an aggregate of up to 4,651,162 common shares at a price of $2.15 per share (for aggregate gross proceeds of up to $10,000,000 in the United States to accredited investors.

  • GlobeNewswire2 months ago

    Zomedica Announces Up to $10 Million Private Offering of Common Shares

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (the "Company"), a veterinary diagnostic and pharmaceutical company, today announced that it has commenced a private offering of its common shares, without par value. The Company is offering an aggregate of up to 4,651,162 common shares at a price of $2.15 (C$2.75) per share (for aggregate gross proceeds of up to $10,000,000 (C$12,790,700)) in the United States to accredited investors only pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder.

  • ACCESSWIRE2 months ago

    Wired News – Zomedica Inks Deal with Seraph to Develop and Market Seraph’s Novel Pathogen Detection System for Veterinarians

    LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on Zomedica Pharma Corp. (NYSE: ZOM) ("Zomedica"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZOM as the Company's latest news hit the wire. On May 10, 2018, the Company announced that it has inked a deal with Seraph Biosciences, Inc. ("Seraph"), which is a human biomedical device organization, thereby securing exclusive global veterinary industry rights to develop and market Seraph's novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument. Active-Investors.com is currently working on the research report for Catalent, Inc. (NYSE: CTLT), which also belongs to the Healthcare sector as the Company Zomedica Pharma.

  • GlobeNewswire2 months ago

    Zomedica Signs Agreement With Seraph Biosciences for Innovative Veterinary Point-of-Care Diagnostic

    Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced it has entered into a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. (“Seraph”), a human biomedical device company. Under the terms of this agreement, Zomedica will have exclusive global veterinary industry rights to develop and market a novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument. Leveraging principles of Raman spectroscopy, Zomedica and Seraph are partnering to bring human diagnostic technology to veterinarians, beginning with the examination of urine and fecal samples.

  • GlobeNewswire2 months ago

    Zomedica to Present at 2018 Disruptive Growth & Healthcare Conference

    ANN ARBOR, Mich., May 07, 2018-- Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, today announced that it will present at the 2018 Disruptive Growth & Healthcare Conference ...

  • ACCESSWIRE4 months ago

    SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM)

    NEW YORK, NY / ACCESSWIRE / March 26, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...

  • ACCESSWIRE8 months ago

    SeeThruEquity Initiates Coverage on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) with a Price Target of $3.24

    Initiating Coverage with a Price Target of US $3.24 NEW YORK, NY / ACCESSWIRE / December 1, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and ...